Global Surgical / Embolization Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Surgical / Embolization Market Overview

The Surgical / Embolization Market was valued at USD 4.28 billion in 2025 and is projected to reach USD 8.84 billion by 2033, growing at a CAGR of 9.50% from 2026 to 2033. The market is witnessing steady growth driven by the rising prevalence of cancer and neurovascular disorders, increasing demand for minimally invasive procedures, and continuous advancements in embolic materials and interventional radiology technologies.

The growing burden of liver cancer, brain aneurysms, and uterine fibroids, along with a global shift toward image-guided and catheter-based treatments, is significantly boosting the adoption of embolization procedures. In addition, improved hospital infrastructure, expanding interventional radiology capabilities, and increasing preference for targeted therapies with reduced recovery time are accelerating market expansion across both developed and emerging economies.

Key Market Trends & Insights

• North America dominated the Surgical / Embolization Market with the largest revenue share of 38.6% in 2025, supported by advanced interventional radiology infrastructure, high procedure volumes, and strong adoption of minimally invasive therapies.
• The Embolic Agents segment led the market with a 44.2% share in 2025, driven by their extensive clinical use across oncology, neurovascular, and peripheral vascular interventions.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 8.1% from 2026 to 2033, fueled by rising cancer incidence, improving healthcare infrastructure, and expanding access to interventional radiology in China, India, and Southeast Asia.
• Flow Diverters are the fastest-growing product type, projected to register a CAGR of 8.2%, reflecting the surge in increasing adoption in complex intracranial aneurysm treatments.
• The Transarterial Chemoembolization (TACE) segment dominated the procedure type category with a 29.5% revenue share in 2025, led by its widespread use in liver cancer (hepatocellular carcinoma) treatment.
• Oncology accounted for 46.8% of the market, preferred by the extensive use of embolization in tumor management, especially liver, kidney, and lung cancers.
• The Neurology segment is the fastest-growing application category, with a CAGR of 8.3%, driven by the increasing incidence of brain aneurysms and neurovascular disorders.

Market Size & Forecast

• Global Market Value (2025): USD 4.28 Billion
• Expected Market Value (2033): USD 8.84 Billion
• Forecast CAGR (2026–2033): 9.50%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia Pacific

Report Scope and Surgical / Embolization Market Segmentation

Surgical / Embolization Market Trends

Trend: Expansion of Image-Guided Precision Embolization Procedures

Interventional radiology is increasingly shifting toward high-precision, image-guided embolization procedures using advanced CT, MRI, and digital subtraction angiography systems to improve targeting accuracy and clinical outcomes. The adoption of drug-eluting microspheres, liquid embolics, and real-time navigation tools is enhancing procedural success rates while reducing recurrence and complication risks. Hospitals and specialty centers are also integrating hybrid operating rooms to enable seamless imaging and intervention workflows, improving efficiency across complex vascular cases, while AI-based imaging support is improving lesion detection and procedural planning. for instance transarterial chemoembolization in liver cancer treatment and uterine fibroid embolization procedures.

Surgical / Embolization Market Dynamics

Key Market Driver: Rising Prevalence of Cancer and Neurovascular Disorders

The increasing global burden of cancer, particularly liver, kidney, and lung tumors, along with rising cases of brain aneurysms and vascular malformations, is significantly driving demand for embolization procedures as minimally invasive treatment options. Growing preference for targeted therapies that reduce hospital stay, lower complication rates, and preserve healthy tissue is further accelerating adoption across hospitals and interventional radiology centers. Expanding screening programs and improved diagnostic imaging are also contributing to earlier detection and higher procedural volumes worldwide, for instance hepatocellular carcinoma embolization and brain aneurysm coil embolization.

Key Restraint/Challenge: High Cost of Advanced Embolization Devices and Procedures

A major restraint in the global embolization market is the high cost associated with advanced embolic materials, imaging systems, and interventional procedure infrastructure, which limits accessibility in low- and middle-income healthcare systems. The requirement for highly skilled interventional radiologists, specialized cath lab setups, and expensive single-use devices further increases overall procedural cost. Reimbursement limitations in several regions also restrict widespread adoption despite clinical benefits, for instance drug-eluting bead embolization systems and flow diversion devices used in neurovascular procedures

Key Market Opportunity: Expansion of Outpatient and AI-Assisted Embolization Platforms

The integration of outpatient-based embolization procedures and AI-assisted image guidance systems presents a major growth opportunity in the market by improving procedural efficiency and reducing hospital resource dependency. Development of minimally invasive techniques suitable for ambulatory surgical centers is expanding access to treatment in cost-sensitive regions while maintaining clinical effectiveness. AI-enabled planning tools and robotic-assisted catheter navigation are expected to enhance precision and scalability of complex vascular interventions, for instance prostate artery embolization in outpatient clinics and AI-guided neurovascular aneurysm embolization procedures

Surgical / Embolization Market Scope

The surgical / embolization market is segmented on the basis of product type, procedure type, application, and end user.

• By Product Type

On the basis of product type, the Surgical / Embolization Market is segmented into embolic agents, embolization coils, flow diverters, vascular plugs, detachable balloons, and delivery devices. The Embolic Agents segment dominated the market with 44.2% share in 2025, owing to their extensive clinical use across oncology, neurovascular, and peripheral vascular interventions. These agents, including microspheres, liquid embolics, and PVA particles, offer high precision in vessel occlusion and tumor targeting. Their adaptability across multiple disease indications makes them a preferred choice for interventional radiologists. Increasing adoption in minimally invasive cancer treatments such as TACE and TARE further strengthens dominance. Continuous innovation in drug-eluting and biodegradable embolics is improving treatment outcomes and reducing recurrence rates. Hospitals widely prefer embolic agents due to their versatility and strong clinical evidence base.

The Flow Diverters segment is expected to register the fastest growth at a CAGR of 8.2% from 2026 to 2033, driven by increasing adoption in complex intracranial aneurysm treatments. These devices are increasingly preferred over traditional coiling techniques for large and wide-neck aneurysms. Advancements in neurovascular device design and improved safety profiles are expanding clinical acceptance. Rising prevalence of brain aneurysms and stroke-related conditions is further boosting demand. Growing availability of trained neurointerventional specialists is supporting procedural expansion. Expanding approvals for next-generation flow diversion devices in emerging markets is also accelerating growth.

• By Procedure Type

On the basis of procedure type, the Surgical / Embolization Market is segmented into Transcatheter Arterial Embolization (TAE), Transarterial Chemoembolization (TACE), Transarterial Radioembolization (TARE), Neurovascular Embolization, and Peripheral Embolization. The Transarterial Chemoembolization (TACE) segment dominated the market with 29.5% share in 2025, primarily due to its widespread use in liver cancer (hepatocellular carcinoma) treatment. TACE combines targeted chemotherapy with arterial blockage, improving drug retention in tumors while minimizing systemic toxicity. Its high clinical efficacy in intermediate-stage liver cancer makes it a standard treatment globally. Increasing liver cancer incidence linked to hepatitis and alcohol-related liver disease further supports demand. Strong reimbursement frameworks in developed healthcare systems are reinforcing adoption. Hospitals and oncology centers prefer TACE due to its established clinical guidelines and repeatability.

The Neurovascular Embolization segment is expected to witness the fastest growth at a CAGR of 8.5% from 2026 to 2033, driven by rising cases of brain aneurysms, AVMs, and ischemic stroke interventions. Increasing adoption of minimally invasive neurointerventional techniques is improving patient survival rates. Technological advancements in microcatheters and detachable coils are enhancing procedural precision. Growing availability of hybrid operating rooms is enabling complex neurovascular procedures. Rising geriatric population is also contributing to higher disease incidence. Expanding training programs in neurointervention across emerging economies is further accelerating market growth.

• By Application

On the basis of application, the Surgical / Embolization Market is segmented into oncology, neurology, urology, gynecology, peripheral vascular diseases, gastrointestinal bleeding, and trauma & emergency bleeding control. The Oncology segment dominated the market with approximately 46.8% share in 2025, driven by extensive use of embolization in tumor management, especially liver, kidney, and lung cancers. Embolization is widely used to cut off blood supply to tumors, improving survival outcomes and reducing tumor size before surgery. Increasing global cancer burden is significantly boosting procedural volumes. Advancements in drug-eluting embolic agents are improving therapeutic precision. Hospitals are increasingly integrating embolization into standard oncology treatment pathways. Rising preference for minimally invasive cancer therapies further strengthens dominance.

The Neurology segment is expected to register the fastest growth at a CAGR of 8.3% from 2026 to 2033, driven by increasing incidence of brain aneurysms and neurovascular disorders. Growing adoption of coil embolization and flow diversion techniques is transforming neurological treatment approaches. Improved imaging technologies are enabling early diagnosis and intervention. Rising stroke prevalence globally is increasing emergency neurovascular procedures. Expanding neurointerventional expertise in emerging markets is supporting adoption. Continuous innovation in neurovascular devices is further accelerating clinical usage.

• By End User

On the basis of end user, the Surgical / Embolization Market is segmented into hospitals, ambulatory surgical centers (ASCs), specialty clinics, and interventional radiology centers. The Hospitals segment dominated the market with 61.3% share in 2025, owing to the availability of advanced imaging infrastructure, skilled interventional radiologists, and high patient inflow. Hospitals are the primary centers for complex embolization procedures such as oncology and neurovascular interventions. They offer integrated care including diagnosis, intervention, and post-procedure monitoring. Strong capital investment in cath labs and hybrid operating rooms supports dominance. Emergency care capabilities also make hospitals the preferred choice for trauma-related embolization. Established reimbursement systems further strengthen hospital-based procedures.

The Ambulatory Surgical Centers (ASCs) segment is expected to witness the fastest growth at a CAGR of 7.9% from 2026 to 2033, driven by the shift toward outpatient minimally invasive procedures. ASCs offer cost-effective treatment options with reduced hospital stay and faster recovery times. Technological advancements are enabling safe performance of select embolization procedures outside hospitals. Increasing patient preference for convenience and affordability is boosting adoption. Expanding healthcare infrastructure in emerging economies is supporting ASC growth. Growing procedural standardization is making embolization more suitable for outpatient settings.

Surgical / Embolization Market Regional Analysis

North America dominated the Surgical / Embolization Market with the largest revenue share of 38.6% in 2025, supported by advanced interventional radiology infrastructure, high procedure volumes, and strong adoption of minimally invasive therapies. The region also benefits from a high prevalence of cancer and neurovascular disorders, well-established reimbursement frameworks, and rapid adoption of next-generation embolic agents and flow diversion devices. Increasing use of image-guided therapies, strong clinical research activity, and widespread availability of hybrid operating rooms continue to strengthen North America’s leadership position in the global market.

U.S. Surgical / Embolization Market Insight

The U.S. surgical / embolization market is witnessing strong growth due to rising prevalence of cancer and neurovascular disorders, advanced interventional radiology infrastructure, and high adoption of minimally invasive treatment procedures. The country’s mature healthcare ecosystem, along with increasing use of image-guided embolization techniques and next-generation embolic agents, is driving demand across hospitals, ambulatory surgical centers, and specialty clinics. In addition, strong reimbursement support, continuous clinical research activities, and rapid adoption of AI-assisted interventional systems are accelerating embolization procedure volumes across the United States.

Europe Surgical / Embolization Market Insight

The Europe surgical / embolization market remains a major contributor to global revenue, driven by strong healthcare systems, established interventional radiology practices, and increasing demand for minimally invasive procedures. The widespread use of embolization in oncology, neurovascular, and gynecology applications is supporting market expansion across the region. Increasing investments in hybrid operating rooms, strict clinical guidelines, and growing adoption of advanced embolic materials continue to enhance procedural outcomes throughout Europe.

U.K. Surgical / Embolization Market Insight

The U.K. surgical / embolization market is experiencing steady growth, supported by rising adoption of interventional radiology techniques in public healthcare systems and increasing demand for outpatient minimally invasive procedures. Growing investments in advanced imaging infrastructure and expanding use of embolization for oncology and neurovascular conditions are contributing to market growth. Furthermore, integration of digital imaging, AI-assisted diagnostics, and improved hospital capabilities is strengthening procedural efficiency and expanding clinical adoption in the U.K.

Germany Surgical / Embolization Market Insight

The Germany surgical / embolization market is expanding steadily due to its strong medical device ecosystem, advanced hospital infrastructure, and increasing adoption of image-guided vascular interventions. Hospitals and specialized clinics are increasingly utilizing embolization for cancer treatment, stroke management, and peripheral vascular diseases. Continuous advancements in embolic agents, flow diverters, and catheter-based technologies, along with strong clinical research activity, are further driving market growth in Germany.

Asia-Pacific Surgical / Embolization Market Insight

The Asia-Pacific surgical / embolization market is expected to witness rapid growth, driven by rising cancer incidence, expanding healthcare infrastructure, and increasing awareness of minimally invasive treatment options. Growing adoption of interventional radiology techniques in countries such as China, India, and Japan is supporting regional expansion. In addition, increasing investments in hospital modernization, rising medical tourism, and improved access to advanced embolization procedures are accelerating market growth across the region.

Japan Surgical / Embolization Market Insight

The Japan surgical / embolization market is witnessing consistent growth due to strong adoption of advanced medical technologies, aging population, and high prevalence of cancer and cerebrovascular disorders. Healthcare providers are increasingly using embolization techniques for precise, minimally invasive treatment across oncology and neurovascular applications. Moreover, integration of high-resolution imaging systems and next-generation embolic materials is further enhancing procedural accuracy and supporting market expansion in Japan.

China Surgical / Embolization Market Insight

The China surgical / embolization market is growing rapidly, driven by increasing burden of cancer, expanding hospital infrastructure, and rising government focus on advanced medical treatments. Growing adoption of interventional radiology procedures across tertiary hospitals is significantly boosting market demand. In addition, increasing investments in medical technology, rising awareness of minimally invasive therapies, and expanding availability of skilled specialists are positioning China as one of the fastest-growing markets globally for embolization procedures.

Surgical / Embolization Market Share

The surgical / embolization industry is primarily led by well-established companies, including:

• Penumbra, Inc. (U.S.)
• Boston Scientific Corporation (U.S.)
• Medtronic (Ireland)
• Johnson & Johnson Services, Inc. (U.S.)
• Terumo Corporation (Japan)
• Merit Medical Systems, Inc. (U.S.)
• Cook (U.S.)
• Stryker (U.S.)
• Sirtex Medical Pty Ltd (Australia)
• BTG International Ltd (U.K.)
• Teleflex Incorporated (U.S.)
• Cardinal Health, Inc. (U.S.)
• Kaneka Corporation (Japan)
• Asahi Intecc Co., Ltd. (Japan)
• MicroVention, Inc. (U.S.)
• Braun SE (Germany)
• LivaNova PLC (U.K.)
• Meril Life Sciences Pvt. Ltd. (India)
• Balton Sp. z o.o. (Poland)
• Wallaby Medical (U.S.)

Latest Developments in Surgical / Embolization Market

• In December 2025, Johnson & Johnson MedTech received FDA approval for expanded use of its TRUFILL™ n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System for treating chronic subdural hematoma via middle meningeal artery embolization. The approval expands the clinical application of liquid embolic therapy in neurovascular interventions, enabling minimally invasive treatment of patients with recurrent brain bleeding conditions. It strengthens the role of embolization as an alternative to open neurosurgical procedures and improves recovery outcomes with reduced hospitalization time. This development marks a significant advancement in neurointerventional embolization therapies
• In March 2025, the U.S. FDA classified Medtronic’s Pipeline Vantage Embolization Device recall as “most serious” due to safety concerns linked to aneurysm treatment complications. The device was associated with risks such as thrombosis, stroke, and improper vessel wall attachment. The recall impacted global neurovascular treatment practices and triggered regulatory scrutiny across multiple regions. This incident highlighted ongoing safety challenges in flow diversion technologies used in neurovascular embolization procedures
• In June 2024, Boston Scientific received FDA clearance for its EMBOLD™ Fibered Detachable Coil for peripheral vascular embolization procedures. The coil is designed to improve controlled occlusion of blood vessels in peripheral and interventional oncology applications. It enhances precision placement and reduces the risk of coil migration during procedures, expanding treatment safety and effectiveness. This approval strengthened Boston Scientific’s embolization portfolio in minimally invasive vascular interventions and supported growing demand for advanced embolic devices
• In February 2024, Terumo Corporation received CE Mark approval for HydroPearl® Microspheres for embolization procedures in Europe. The approval enables commercialization for treating hypervascular tumors and uterine fibroids. These microspheres offer improved uniformity and controlled drug delivery in embolization therapy. This expansion strengthens Terumo’s presence in interventional oncology markets and supports growing global demand for advanced particle-based embolic agents
• In January 2024, Merit Medical received FDA clearance for expanded use of Embosphere® Microspheres in prostatic artery embolization for benign prostatic hyperplasia (BPH). This expanded indication increases the use of embolization beyond oncology into urology applications. The microspheres enable targeted reduction of blood flow to the prostate, helping relieve BPH symptoms without surgery. The development supports increasing adoption of outpatient embolization procedures and strengthens Merit Medical’s position in particle embolization technologies

SKU-76036